Evidence map›Paper›PMID 39361729›Full record

ArticleEmerging microbes & infections2024

Omicron-specific ultra-potent SARS-CoV-2 neutralizing antibodies targeting the N1/N2 loop of Spike N-terminal domain.

Xiao Niu, Zhiqiang Li, Jing Wang, Fanchong Jian, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Shuo Du, Zhiying Zhang, Qianran Wang and 13 more

Abstract read
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Structural Immunology of SARS-CoV-2.Immunological reviews · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Xiao NiuBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Zhiqiang LiChangping Laboratory, Beijing, People's Republic of China.
Jing WangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Fanchong JianBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Yuanling YuChangping Laboratory, Beijing, People's Republic of China.
Weiliang SongBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Ayijiang YisimayiBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Shuo DuChangping Laboratory, Beijing, People's Republic of China.
Zhiying ZhangSchool of Life Sciences, Peking University, Beijing, People's Republic of China.
Qianran WangChangping Laboratory, Beijing, People's Republic of China.
Jing WangChangping Laboratory, Beijing, People's Republic of China.
Ran AnChangping Laboratory, Beijing, People's Republic of China.
Yao WangChangping Laboratory, Beijing, People's Republic of China.
Peng WangChangping Laboratory, Beijing, People's Republic of China.
Haiyan SunChangping Laboratory, Beijing, People's Republic of China.
Lingling YuChangping Laboratory, Beijing, People's Republic of China.
Sijie YangBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Tianhe XiaoBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Qingqing GuChangping Laboratory, Beijing, People's Republic of China.
Fei ShaoChangping Laboratory, Beijing, People's Republic of China.
Youchun WangChangping Laboratory, Beijing, People's Republic of China.ORCID 0000-0001-9769-5141
Junyu XiaoChangping Laboratory, Beijing, People's Republic of China.
Yunlong CaoBiomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A multitude of functional mutations continue to emerge on the N-terminal domain (NTD) of the spike protein in SARS-CoV-2 Omicron subvariants. Understanding the immunogenicity of Omicron NTD and the properties of antibodies elicited by it is crucial for comprehending the impact of NTD mutations on viral fitness and guiding vaccine design. In this study, we find that most of NTD-targeting antibodies isolated from individuals with BA.5/BF.7 breakthrough infection (BTI) are ancestral (wild-type or WT)-reactive and non-neutralizing. Surprisingly, we identified five ultra-potent neutralizing antibodies (NAbs) that can only bind to Omicron but not WT NTD. Structural analysis revealed that they bind to a unique epitope on the N1/N2 loop of NTD and interact with the receptor-binding domain (RBD) via the light chain. These Omicron-specific NAbs achieve neutralization through ACE2 competition and blockage of ACE2-mediated S1 shedding. However, BA.2.86 and BA.2.87.1, which carry insertions or deletions on the N1/N2 loop, can evade these antibodies. Together, we provided a detailed map of the NTD-targeting antibody repertoire in the post-Omicron era, demonstrating their vulnerability to NTD mutations enabled by its evolutionary flexibility, despite their potent neutralization. These results revealed the function of the indels in the NTD of BA.2.86/JN.1 sublineage in evading neutralizing antibodies and highlighted the importance of considering the immunogenicity of NTD in vaccine design.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19EpitopesSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2HumansMutationProtein DomainsAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2 competitionantibodiesN1/N2 loopN-terminal domainSARS-CoV-2

Identifiers

PMID39361729
PMCPMC11520098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.